Among 26 evaluable patients with clear cell ovarian or endometrial cancer, the objective response rate with the regimen was ...

Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have ...

A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

Invasive bladder cancer can be treated through immunotherapy involving Bacillus Calmette-Guérin (BCG), but some 40%-60% of ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

Approved by the Medicines and Healthcare products Regulatory Agency (MHRA), the injectable will cut down on immunotherapy ...

NASHVILLE, Tenn. (WTVF) — June is Cancer Immunotherapy Month. Immunotherapy drugs have been on the market for more than a decade. Dr. David Spigel is a medical oncologist at the Sarah Cannon Research ...

Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...